Abstract
The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.
Original language | English (US) |
---|---|
Pages (from-to) | 794-797 |
Number of pages | 4 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 44 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2000 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases